I think early days in the states will probably be hard unless they have interest already. The ASX is notorious for being a pretty poor place to be listed though, so its a bit of a 'whats there to lose' scenario.
The conference in January and lots of potential avenues to pursue give me and others hope that one of their many promising assets can gain traction. The board, Bob and others definitely work their contact lists. Theres a lot of cash on the sidelines in the US, maybe the timing is gonna be just right, who knows
It's a big risk yes, but thats Biotech. I do feel for those who have averages significantly higher, starting way up there. If I wasnt invested, I think of the biotechs I follow, IHL is definitely very high on the value proposition their market cap is absolutely too low for their assets right now - but there is absolutely no guarantee that will change for the better.
IHL Price at posting:
6.3¢ Sentiment: None Disclosure: Held
